LUVASE 0.63 is a Levosalbutamol 0.63 mg/2.5 mL respiratory nebuliser formulation designed for targeted bronchodilator support in patients experiencing reversible airway narrowing and bronchospasm. Its unit-dose respule format promotes convenient administration through a nebuliser and can be particularly useful in paediatric and respiratory-care settings where coordinated inhaler use may be challenging. A focused PCD Pharma Respiratory & Nebuliser portfolio product.
It is used for relief of bronchospasm and wheezing in appropriate respiratory conditions.
It delivers the medication directly into the airways, which can be useful when inhaler technique is difficult.
Yes, beta-2 agonists may occasionally increase heart rate.
No, it is a bronchodilator, not an antibiotic.
Use only according to the prescribed nebulisation dose and frequency. The nebuliser should be used with proper technique and cleaned appropriately after use to reduce contamination. Inform the physician about heart disease, arrhythmias, hyperthyroidism or diabetes. Do not increase frequency without advice. Persistent wheezing, severe breathlessness, cyanosis or inadequate response requires urgent medical evaluation.
Levosalbutamol is generally well tolerated when administered at the prescribed dose, although tremor, nervousness, headache, dizziness, palpitations and increased heart rate may occur. Some patients may experience muscle cramps or mild throat irritation following nebulisation. Excessive or frequent administration can increase cardiovascular and metabolic adverse effects. Patients developing significant palpitations, chest discomfort, severe tremor or worsening breathing difficulty should receive prompt medical assessment.
LUVASE 0.63: Levosalbutamol is a selective beta-2 adrenergic agonist that acts primarily on bronchial smooth muscle. By stimulating beta-2 receptors, it activates intracellular pathways that increase cyclic AMP and promote relaxation of constricted airways. This results in bronchodilation and improved airflow, helping reduce wheezing, chest tightness and breathing difficulty associated with reversible bronchospasm. Its nebulised delivery allows the medicine to reach the lower respiratory tract directly.
